(MENAFN- ProactiveInvestors)
(ASX:UBI) is taking step forward with Siemens Healthcare Diagnostics receiving CE Mark approval for the jointly developed Xprecia Stride™ Coagulation Analyzer the first point-of-care coagulation analyser.
This indicates the product is fully compliant with all relevant EU legislation and allows it to be sold within 31 countries operating in the European Economic Area.
The CE marking follows receipt of two commercial orders from Siemens for the production and supply of PT-INR (prothrombin time) test strips by .
Xprecia Stride™ is PT-INR testing system used to monitor the application of the anti-coagulant therapy Warfarin.
will exclusively manufacture PT-INR strips for Siemens at its existing plant in Rowville Victoria.
It is estimated about 10 million patients globally are taking Warfarin. Patients are prescribed the drug for a variety of reasons including the treatment of blood clots in the veins or certain heart conditions which increase the likelihood of a potentially life-threatening clot forming.
Patients on Warfarin require frequent testing of the clotting tendency of their blood. PT-INR testing allows physicians to adjust patient doses for diet and lifestyle changes.
The worldwide point-of-care coagulation testing market was estimated at around US$1.0 billion in 2014 and is forecast to grow by 9% per annum to US$1.4 billion by 2018.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.